Ma’an Amad
Boehringer Ingelheim (Egypt)(EG)Boehringer Ingelheim (Canada)(CA)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, HIV Research and Treatment, Hepatitis C virus research, Biochemical and Molecular Research, Hepatitis B Virus Studies
Most-Cited Works
- → A Novel Human Cytochrome P450, CYP26C1, Involved in Metabolism of 9-cis and All-trans Isomers of Retinoic Acid(2003)211 cited
- → CYP2U1, a Novel Human Thymus- and Brain-specific Cytochrome P450, Catalyzes ω- and (ω-1)-Hydroxylation of Fatty Acids(2004)185 cited
- → Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1(2014)176 cited
- → Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease(2010)109 cited
- → Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor(2014)98 cited
- → Thiotetrazole alkynylacetanilides as potent and bioavailable non-nucleoside inhibitors of the HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases(2007)53 cited
- → Discovery and Synthesis of C-Nucleosides as Potential New Anti-HCV Agents(2014)35 cited
- → Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: Structure–activity relationships (SAR) of the C3-phenyl moiety(2013)21 cited
- → The Liver Partition Coefficient-Corrected Inhibitory Quotient and the Pharmacokinetic-Pharmacodynamic Relationship of Directly Acting Anti-Hepatitis C Virus Agents in Humans(2012)20 cited
- → Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor(2011)15 cited